Article Detail - JE Part A
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454)- R8 - Effective September 26, 2024
Date Posted: September 26, 2024
This Local Coverage Article (LCA) has been revised under contractor numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).
Effective Date: September 26, 2024
Summary of Changes:
Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to read "muscle-invasive bladder". This revision is due to new covered test that has successfully completed a TA and is effective for 4/19/2022.
Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "ovarian". This revision is due to new covered test that has successfully completed a TA and is effective for 12/14/2023.
Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "(neoadjuvant)". This revision is due to new covered test that has successfully completed a TA and is effective for 12/20/2023.
Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #2 to add "in patients with a personal history of cancer" and "Natera". Formatting was corrected throughout the article. This revision is due to covered test that has successfully completed a TA and is effective for 5/12/2022.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.
